LATEST CONTENT –
“Ovarian Cancer Genetic Labs Physician/Patient Postcard”
Every patient with ovarian cancer should be offered testing aimed at informing targeted therapeutic decisions. This quick-reference, non-exhaustive guide provides a snapshot of germline and somatic testing options available for patients with ovarian cancer. Physicians and patients alike are encouraged to reference this PDF to printable postcard for more information about various labs, counseling options, and insurance information.
“Real-World Palliative Care in GYN Oncology: WHO (can do it), WHAT (is it), WHEN (to start), WHERE (can we do this) and WHY (is it so important)”
A round table discussion with a range of experts from academic centers to small community practice present examples of integrating palliative care in a variety of practice settings.
Moderator: Melissa Hardesty, MD, Alaska Women’s Cancer Care,
Speakers: Linda Smith, MD, Alaska Women’s Cancer Care, Kate Lally, MD FAAHPM, Dana Farber Cancer Institute, Carolyn Lefkowits, MD, MPH, UC Health Cancer Care, Lori Spoozak, MD, MHS, FACOG, FACS, University of Kansas, and Michael Pearl, MD, FACOG, FACS, FAAHPM, Stony Brook University Hospital.
“Conversations in The Clinic: Patient Perspectives on Genetic Testing” Podcast
Listeners will learn about the importance of genetic testing for ovarian cancer from a genetic counselor and a physician, and most importantly, from a patient.
Moderator: Ashley Stuckey, MD
Speakers Todd Tillmanns, MD, FACOG, West Cancer Center, and Leigha Senter-Jamieson, MS, LGC, Ohio State College of Medicine
“Perfecting Placement of PARPS: Preventing Progression of Ovarian Cancer Webinar”
In the fast-paced world of PARP inhibitor approvals in both the setting of maintenance and therapy in ovarian cancer, this panel of experts will assist practitioners to understand how to order germline and somatic testing for BRCA and HRD mutations. Speakers will discuss sequencing of PARP inhibitors as well as mitigating side effects. Additionally, they will discuss future directions for the use of PARP inhibitors as well as briefly discuss resistance to PARP inhibitors.
Moderator: John Farley, MD, COL, FACOG, FACS, Dignity Health – Cancer Institute, St. Joseph’s Hospital and Medical Center
Speakers: Premal Thaker, MD, MS, Washington University in St. Louis Siteman Cancer Center, Mary (“Maggie”) Mullen, MD, Washington University in St. Louis School of Medicine, and Todd Tillmanns, MD, FACOG, West Cancer Center
